Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?

11 Jun 2018

Abstract excerpt

Azacitidine is the only drug proven to prolong overall survival (OS) in patients with higher-risk myelodysplastic syndromes (HR-MDS) in the large randomized trial AZA-001 with a median OS of 24.5 months among azacitidine-treated patients vs. 15.0 months in the conventional care regimens (CCR) arm, with a hazard ratio of 0.58; p = 0.0001 1 . Two-year OS probability was 51% in azacitidine arm compared with 26% in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29891916
DOI: 10.1038/s41408-018-0081-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?PMID 29891916Read ↗

Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.Semantic proximity Read ↗

Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine.Semantic proximity Read ↗

Survival of myelodysplastic syndrome patients after azacitidine therapy.Semantic proximity Read ↗

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.Semantic proximity Read ↗

A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612Semantic proximity Read ↗

Venetoclax and azacitidine compared with intensive chemotherapy for adverse-risk acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in first complete remission: a multicenter study of TROPHY group.Semantic proximity Read ↗

Cytidine deaminase activity predicts clinical outcome of azacitidine in real-world MDS patientsSemantic proximity Read ↗

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromesSemantic proximity Read ↗

Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemiaSemantic proximity Read ↗

New Ways to Use DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic SyndromeSemantic proximity Read ↗

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trialSemantic proximity Read ↗

A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.